

trial of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or hydrocolloid dressings for venous ulcers. *J Vasc Surg.* 2007 Jan; 45(1):134-141. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17210398>.

RATIONALE: A report of a randomised trial, which found that patients with venous leg ulcers treated with four-layer compression are significantly more likely to heal than those treated with an adhesive single-layer bandage.

10. Palfreyman SJ, Nelson EA, Michaels JA. Dressings for venous leg ulcers: systematic review and meta-analysis. *BMJ.* 2007 Aug; 335(7613):244. Available from:

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939774/>.

RATIONALE: A systematic review and meta-analysis reviewing the evidence of the effectiveness of dressings applied to venous leg ulcers. This review explicitly states that multi-layer component compression bandaging is the most effective in the treatment of venous leg ulcers. It also suggests that there is some evidence that cadexomer iodine can aid healing so may be considered as a topical antiseptic.

11. Hill KE, Davies CE, Wilson MJ, Stephens P, Harding KG, Thomas DW. Molecular analysis of the microflora in chronic venous leg ulceration. *J Med Microbiol.* 2003 Apr; 52:365-369.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12676877>.

RATIONALE: A review article stating that routine microbiological sampling of venous leg ulcers without clinical signs of infection is often pointless. It also outlines the potential bacteria found in clinically infected venous leg ulcers and suggests that antibiotics are only recommended in the presence of locally spreading cellulitis or other signs of infection.

12. Public Health England (PHE). UK standards for microbiological investigations: investigation of skin, superficial and non-surgical wound swabs. 2014 May. Available from:

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/391745/B_11i5.2.pdf.

RATIONALE: A PHE document outlining the standards required for bacteriological investigation and processing of skin, superficial and non-surgical wound swabs. This document suggests that routine swab cultures are of questionable clinical value if there is no sign of infection. It also states that specimens should be collected before antimicrobial therapy is started, and provides details on how to optimise results from a wound swab. The guideline describes how to take a microbiological sample and the importance of using appropriate transport medium and transporting the specimen to the microbiology laboratory as soon as possible.

13. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. *Clin Microbiol Rev.* 2001 Apr; 14(2):244-269. Available from:

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC88973/>.

RATIONALE: A highly detailed paper stating that only clinical infection should prompt a practitioner to sample a wound for microbiological analysis, as routine biopsy specimens are impractical in the management of venous leg ulcers. This paper outlines the importance of correct procedure in collecting and transporting microbiological specimens

and including all clinical and patient details on a sample. It is also stated that the majority of open wounds are polymicrobial, but only some of these bacteria cause clinical infection. If infection is present, treatment with topical and systemic antibiotics is crucial, and there is some evidence for the potential benefits of cadexomer iodine as a topical antiseptic.

14. Davies CE, Hill KE, Newcombe RG, Stephens P, Wilson MJ, Harding KG et al. A prospective study of the microbiology of chronic venous leg ulcers to re-evaluate the clinical predictive value of tissue biopsies and swabs. *Wound Repair Regen.* 2007 Jan-Feb; 15(1):17-22.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17244315>.

RATIONALE: A prospective study, which states that no consistent association has been made between colonisation and infection of open leg wounds. This paper also determines that wound biopsies do not contribute significantly to the patient management of venous leg ulcers.

15. Gardner SE, Frantz RA, Saltzman CL, Hillis SL, Park H, Scherubel M. Diagnostic validity of three swab techniques for identifying chronic wound infection. *Wound Repair Regen.* 2006 Sep-Oct; 14(5):548-557. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17014666>.

RATIONALE: A study examining the diagnostic validity of three different swab techniques in identifying chronic wound infection. This paper states that all secondary wounds are colonised by many types of bacteria, but this does not mean that they are infected. Of the 83 wounds analysed in this paper, 30 (36%) were infected. The authors conclude that swab specimens obtained using Levine's technique had the highest accuracy.

16. O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M, Richardson R. Antibiotics and antiseptics for venous leg ulcers (Review). *Cochrane Database Syst Rev.* 2014 Jan; 1:1-156. Available from:

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003557.pub5/pdf/standard>.

RATIONALE: An updated Cochrane review of 45 randomised controlled trials, established to determine the effects of systemic, topical antibiotics and antiseptics on the healing of venous leg ulcers. The authors state that the evidence does not currently support the routine use of systemic antibiotics in venous leg ulcers, especially with the increasing problem of bacterial resistance in the community. There is, however, some evidence in support of cadexomer iodine as a topical preparation. This review suggests that all wounds are colonised by bacteria and, at a certain level, some bacteria can cause significant infection and delay healing. The authors conclude that antibacterial preparations should only be used in cases of clinical infection, as bacterial colonisation alone is not considered adverse to healing.

17. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA, Gould K, editor, Reeves D, editor. Managing skin and soft tissue infections: expert panel recommendations on key decision points. *J Antimicrob Chemother.* 2003 Nov; 52(1):3-17. Available from:

http://jac.oxfordjournals.org/content/52/suppl_1/i3.full.pdf.

RATIONALE: A review paper written by an expert panel, in which the authors state that the first dose of antibiotic therapy should be administered as soon as culture specimens

are obtained. The authors list the likely colonising and infecting pathogens for specific types of skin and soft tissue infections. The importance of considering patient characteristics when determining the correct antibiotic dosing is also underlined. This paper suggests flucloxacillin and clindamycin as the recommended antimicrobial therapy for class 2 and 3 skin and soft tissue infections.

18. Barber S, Lawson PJ, Grove DI. Evaluation of bacteriological transport swabs. *Pathology*. 1998 May; 30(2):179-182. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9643502>.
RATIONALE: A study evaluating various transport swabs for their ability to preserve bacteria for 24 and 48 hours. The authors conclude that swabs using Amies plus charcoal medium have better recovery rates than those using Amies medium alone.
19. Clinical Resource Efficiency Support Team (CREST). Guidelines on the management of cellulitis in adults. 2005 Jun. Available from: <http://www.acutemed.co.uk/docs/Cellulitis%20guidelines,%20CREST,%2005.pdf>.
RATIONALE: An expert consensus outlining the most common infective organisms as streptococci and *Staphylococcus aureus*. The consensus is that people with Class I disease (no signs of systemic toxicity and no uncontrolled comorbidities) can usually be managed on an outpatient basis with oral antibiotics. Flucloxacillin 500mg QDS (or clarithromycin 500mg BD for those with penicillin allergy) are suitable oral antibiotics because they cover both staphylococci and streptococci. Clindamycin 300mg QDS is also recommended as a further alternative for people who do not respond to treatment, or have more severe disease. This document states that most cases of uncomplicated cellulitis can be successfully treated within 1-2 weeks of therapy. Consider outpatient antimicrobial therapy (OPAT) with intravenous treatment in those with Class II disease (systemically unwell or co-morbidity). Patients can usually be switched to oral treatment after 3-5 days when signs and symptoms are improving (decreased temperature, change in white cell count, and decreasing erythema and induration). Those with Class III disease (significant systemic upset, acute confusion, tachycardia, tachypnoea, hypotension or unstable comorbidities) or Class IV disease (patients with sepsis syndrome or severe life threatening infections) should be admitted urgently.
20. British Lymphology Society. Consensus document on the management of cellulitis in lymphoedema. 2015 Apr. Available from: <http://thebls.com/documents/1.pdf>.
RATIONALE: An expert consensus document on the management of cellulitis in lymphoedema. The authors state that flucloxacillin 500mg should be prescribed in the presence of clinical infection (eg pus formation, folliculitis or crusted dermatitis). They also state that if the patient is allergic to penicillin, clarithromycin 500mg or clindamycin 300mg should be prescribed. Doxycycline 200mg is recommended as an alternative if the patient is penicillin-hypersensitive and taking statins (eg simvastatin or atorvastatin). Finally, the authors state that advice should be sought from a local microbiologist if the infection fails to respond to these recommendations.

Acknowledgements

QUICK REFERENCE GUIDE AUTHORS

Prof Cliodna McNulty, Head of Primary Care Unit and Honorary Visiting Professor, Public Health England and Cardiff University

Dr Philippa Moore, Consultant Microbiologist, Gloucestershire Royal Hospital

Prof David Leaper, Visiting Professor, Cardiff University

Jacqui Fletcher, Senior Professional Tutor in the Department of Dermatology and Wound Healing, Cardiff University

Dr Gerry Morrow, Clinical Editor, Clinical Knowledge Summaries

Sarah Alton, Guidance Research Assistant, Public Health England

QUICK REFERENCE GUIDE REVIEWERS

Dr Teferi Abraham, Medical Doctor, Luton and Dunstable University Hospital NHS Foundation Trust

Dr Gavin Barlow, Consultant in Infection, Hull & East Yorkshire Hospitals NHS Trust

Dr Adriana Basarab, Consultant Medical Microbiologist, University Hospital Southampton NHS Foundation Trust

Dr Justin Bendig, Consultant Microbiologist and Joint Head of Department, Epsom and St Helier University Hospitals

Dr Giuseppe Bignardi, Consultant Microbiologist, City Hospitals Sunderland NHS Foundation Trust

Valerie Bailey, Professional Practice Co-ordinator and Wales Union Learning Fund (WULF) Project Manager, Royal College of Nursing

Deri Burgess, Clinical Pharmacist, First Databank

Dr Alleyna Claxton, Consultant Microbiologist, Homerton University Hospital Foundation Trust

Anna Crossley, Professional Lead for Acute Emergency and Critical Care, Royal College of Nursing

Dr Richard Cunningham, Consultant Microbiologist, Plymouth Hospitals NHS Trust

Dr Jayshree Dave, Public Health England (PHE) Consultant Medical Microbiologist, Barts and The London NHS Trust

Dr Jiten Dave, Company Director, Jrd Healthcare Limited

Dr Roopal Dave, General Practitioner, Ealing Park Health Centre

Lynn Davis, Tissue Viability Nurse Specialist, Gloucestershire Hospitals NHS Foundation Trust

Dr Susan Dawson, Consultant Microbiologist, Great Western Hospitals NHS Foundation Trust

Rose Gallagher, Nurse Advisor Infection Prevention and Control, Royal College of Nursing

Dr Roshina Grenadira, General Practitioner (*no longer in practice*)

Dr Shabnam Iyer, Consultant Microbiologist, The Royal Berkshire NHS Foundation Trust

Dr David Jenkins, Consultant Medical Microbiologist and Lead Infection Prevention Doctor, University Hospitals of Leicester NHS Trust

Brenda King, Nurse Consultant, Sheffield Teaching Hospitals NHS Foundation Trust

Andrew Kingsley, Lead Nurse Healthcare Acquired Infections, Northern, Eastern and Western Devon Clinical Commissioning Group

Dr Tom Lewis, Consultant Medical Microbiologist and Lead for Antimicrobial Stewardship, Northern Devon Healthcare NHS

Prof Alasdair MacGowan, Consultant Medical Microbiologist, North Bristol NHS Trust

Dr George Moncrieff, General Practitioner, Bicester Health Centre

Dr Dilip Nathwani, Consultant Physician, NHS Tayside

Prof Andrea Nelson, Professor in Wound Healing, University of Leeds

Dr Paul O'Hallaran, General Practitioner, Hampshire Hospitals NHS Foundation Trust

Rachael Parslow, Development and Communications Co-ordinator, PRODIGY Knowledge

Dr Keith Poskitt, Consultant General and Vascular Surgeon, Gloucestershire Hospitals NHS Foundation Trust

Benjamin Rehman, Director London Medicines Information Service and Chair UK Medicines Information (UKMi), North West London Hospitals

Dr Terry Riordan, Consultant Medical Microbiologist, Royal Devon and Exeter Healthcare NHS Trust

Ruth Ropper, Lead Nurse – Tissue Viability, NHS Lothian

Dr Andrew Seaton, Consultant Physician, NHS Greater Glasgow & Clyde

Dr John Sloss, Consultant Microbiologist, County Durham and Darlington Acute Hospitals NHS Trust

Dr Jane Stockley, Consultant Medical Microbiologist, Worcestershire Acute Hospitals NHS Trust

Dr David Waghorn, Consultant Microbiologist, Buckinghamshire Healthcare NHS Trust

Dr Vivienne Weston, Consultant Microbiologist and Community Infection Control Doctor, Nottingham University Hospitals NHS Trust

Prof Peter Wilson, Consultant Microbiologist, University College London Hospitals

Dr Harry Yoxall, Medical Secretary, Somerset Local Medical Committee

Primary Care Clinicians from Cheltenham Road Surgery, Gloucester

Primary Care Clinicians from Rosebank Surgery, Gloucester

Members of the Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI)

Members of the British Infection Association (BIA)

Members of the British Society for Antimicrobial Chemotherapy (BSAC)

Members of the Public Health England (PHE) Standards Unit

Members of the Royal College of General Practitioners (RCGP)

Members of the Royal College of Nursing (RCN)

For any further information regarding the review process and those involved in the development of this guidance, please email sarah.alton@phe.gov.uk.

Public Health England is an executive agency of the Department of Health, and is fully funded by the UK Government. The Primary Care Unit does not accept funding for the development of this guidance from pharmaceutical companies or other large businesses that could influence the development of the recommendations made.

Any conflicts of interest have been declared and considered prior to the development and dissemination of this guidance. For any detailed information regarding declared conflicts of interest, please email sarah.alton@phe.gov.uk.

Withdrawn March 2020.

Abbreviations

BD = Twice daily

BMI = Body mass index

G = Gram(s)

Mg = Milligram(s)

MRSA = Methicillin-resistant *Staphylococcus aureus*

OPAT = Outpatient antimicrobial therapy

QDS = Four times daily

Withdrawn March 2020.